Ding Fen-gan, Liu Biao, Zhang Xin-hua, Xu Yan, Yu Bo, Zhang Ru-song, He Yan, Ma Heng-hui, Lu Zhen-feng, Zhou Xiao-jun
Department of Pathology, Nanjing General Hospital of Nanjing Command, Nanjing 210002, China.
Zhonghua Bing Li Xue Za Zhi. 2012 Mar;41(3):145-50. doi: 10.3760/cma.j.issn.0529-5807.2012.03.001.
To evaluate the prognostic significance of a new grading and scoring system (based on the new IASLC/ATS/ERS classification) in stage I pulmonary adenocarcinoma, as compared with the WHO grading system.
The clinicopathologic characteristics of 125 patients with stage I pulmonary adenocarcinoma primarily treated by surgical resection were reviewed retrospectively. All cases were classified according to the new IASLC/ATS/ERS classification and graded into three prognostic groups based on the new classification, the Sica scoring system and the WHO grading system, respectively. The differences in prognosis of the three groups were analyzed.
There was a statistically significant correlation between the new grading system and the WHO grading system (P = 0.000). Both of them showed negative correlation with overall survival. The new scoring system however better correlated with disease recurrence and/or metastasis (P = 0.855, P = 0.073 versus P = 0.011). According to univariate Log-rank test, the prognosis correlated with tumor size (P = 0.004), clinical stage (P = 0.000), the WHO grading (P = 0.020), the new grading system (P = 0.000), the new scoring system (P = 0.000), vascular invasion (P = 0.021), and recurrence and/or metastasis (P = 0.000). The Cox regression analysis demonstrated that clinical stage (P = 0.014), the new grading system (P = 0.047), the new scoring system (P = 0.043), and recurrence and/or metastasis (P = 0.018) were significantly independent poor prognostic factors.
The new grading and scoring system shows good correlation with the WHO grading system. Compared with the WHO grading system, the new scoring system based on the new IASLC/ATS/ERS classification provides valuable information in categorizing stage I pulmonary adenocarcinoma cases with different risks of disease recurrence, tumor metastasis and prognosis.
与世界卫生组织(WHO)分级系统相比,评估一种新的分级和评分系统(基于国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新分类)在Ⅰ期肺腺癌中的预后意义。
回顾性分析125例主要接受手术切除的Ⅰ期肺腺癌患者的临床病理特征。所有病例分别根据国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新分类、西卡评分系统和WHO分级系统进行分类,并分为三个预后组。分析三组预后的差异。
新分级系统与WHO分级系统之间存在统计学显著相关性(P = 0.000)。两者均与总生存期呈负相关。然而,新评分系统与疾病复发和/或转移的相关性更好(P = 0.855,P = 0.073,而P = 0.011)。根据单因素对数秩检验,预后与肿瘤大小(P = 0.004)、临床分期(P = 0.000)、WHO分级(P = 0.020)、新分级系统(P = 0.000)、新评分系统(P = 0.000)、血管侵犯(P = 0.021)以及复发和/或转移(P = 0.000)相关。Cox回归分析表明,临床分期(P = 0.014)、新分级系统(P = 0.047)、新评分系统(P = 0.043)以及复发和/或转移(P = 0.018)是显著的独立不良预后因素。
新分级和评分系统与WHO分级系统显示出良好的相关性。与WHO分级系统相比,基于国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新分类的新评分系统在对具有不同疾病复发、肿瘤转移风险和预后的Ⅰ期肺腺癌病例进行分类时提供了有价值的信息。